Insider Selling: Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) CEO Julie So-Young Kim sold 89,090 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $1,523,439.00. Following the transaction, the chief executive officer directly owned 391,489 shares of the company’s stock, valued at $6,694,461.90. The trade was a 18.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.06 on Wednesday, reaching $17.42. The stock had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $16.49 and its two-hundred day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $6.90 billion during the quarter. As a group, research analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership boosted its stake in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after buying an additional 2,854,069 shares in the last quarter. UBS Group AG raised its stake in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after acquiring an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after acquiring an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TAK has been the topic of a number of recent analyst reports. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.